Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure

BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser.

PRNewsWire • Mar 2, 2026

Ginkgo Bioworks Makes Major Pivot

Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 revenue, far below the original $1.1 billion SPAC projection. Management is pivoting by selling the Biosecurity segment, retaining only a minority stake in the new private entity.

Seeking Alpha • Mar 2, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 28, 2026

Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter

Ginkgo Bioworks (NYSE: DNA) shares are down following the company's fourth-quarter and full-year 2025 financial report.

Benzinga • Feb 27, 2026

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

Ginkgo provides an update on its fourth quarter financial results BOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.

PRNewsWire • Feb 26, 2026

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2025 Results Presentation

Presentation and Q&A session scheduled for post-market on Thursday, February 26, 2026 BOSTON, Feb. 19, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com , and a replay will be made available.

PRNewsWire • Feb 19, 2026

Ginkgo Bioworks and Invaio Sciences Enter Collaboration to Develop Manufacturing Technology for Peptide-based Agricultural Products

Collaboration aims to develop a commercialization-ready microorganism to manufacture next-generation peptide crop solutions at grower-friendly costs BOSTON, Feb. 18, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo") and Invaio Sciences, an agricultural biotechnology company leading in nature-positive crop protection solutions, today announced a collaboration to develop strains that can efficiently manufacture peptide-based crop protection inputs. Growers are seeking inputs that protect agricultural crops from pests that are increasingly resistant to conventional chemistry.

PRNewsWire • Feb 18, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts

The latest trading day saw Ginkgo Bioworks Holdings, Inc. (DNA) settling at $9, representing a -3.12% change from its previous close.

Zacks Investment Research • Feb 18, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Ginkgo Bioworks Holdings, Inc. (DNA) reached $9.23 at the closing of the latest trading day, reflecting a -9.06% change compared to its last close.

Zacks Investment Research • Feb 11, 2026

Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark

Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratory Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis GPT-5-driven autonomous lab executed over 36,000 experiments Ginkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven science BOSTON, Feb. 5, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has demonstrated, in collaboration with OpenAI, an AI system that autonomously designed, executed, and learned from biological experiments with minimal human involvement. In a new preprint, the company reports the system reduced cell-free protein synthesis reaction costs by 40% relative to state of the art, while running 36,000 experimental conditions across six iterative cycles.

PRNewsWire • Feb 5, 2026